Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Alzheimer's & Dementia

• Publication date

  2015-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jalz.2014.02.004PMID 24795085PMCID PMC4386839
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differences Between Early- and Late-Onset Alzheimer Disease and Stability During the Course of Disease

  2017cited by this paper
• 2016 Alzheimer's disease facts and figures

  2016cited by this paper
• Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

  2014cited by this paper
• Cerebrospinal fluid biomarkers of Alzheimer’s disease

  2014cited by this paper
• Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid

  2013cited by this paper
• Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study.

  2013cited by this paper
• Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid

  2013cited by this paper
• Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.

  2013cited by this paper
• Clinical and biomarker changes in dominantly inherited Alzheimer's disease.

  2012cited by this paper
• Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease

  2012cited by this paper
• CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings

  2012cited by this paper
• Cerebrospinal Fluid Biomarkers and Proximity to Diagnosis in Preclinical Familial Alzheimer’s Disease

  2012cited by this paper
• Correlation of Amyloid PET Ligand Florbetapir F 18 Binding With A&bgr; Aggregation and Neuritic Plaque Deposition in Postmortem Brain Tissue

  2012cited by this paper
• Perspectives for Multimodal Neurochemical and Imaging Biomarkers in Alzheimer's Disease

  2012cited by this paper
• Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010

  2012cited by this paper
• Development of biomarkers to chart all Alzheimer's disease stages: The royal road to cutting the therapeutic Gordian Knot

  2012cited by this paper
• Practical Guidelines for the Recognition and Diagnosis of Dementia

  2012cited by this paper
• Fluid biomarkers in Alzheimer disease.

  2012influential reference
• Brain imaging in Alzheimer disease.

  2012influential reference
• Longitudinal Cerebrospinal Fluid Biomarkers over Four Years in Mild Cognitive Impairment

  2012cited by this paper
• Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update.

  2012cited by this paper
• Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.

  2012cited by this paper
• Alzheimer's disease.

  2011cited by this paper
• 2011 Alzheimer's disease facts and figures

  2011cited by this paper
• The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011influential reference
• Phosphorylated tau 231, memory decline and medial temporal atrophy in normal elders.

  2011cited by this paper
• Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.

  2011cited by this paper
• Qualification Opinion of Alzheimer ’ s Disease Novel Methodologies / biomarkers for BMS-708163

  2011cited by this paper
• Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011influential reference
• Neurodegenerative disease biomarkers: guideposts for disease prevention through early diagnosis and intervention.

  2011cited by this paper
• The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers

  2011influential reference
• Cerebrospinal fluid biomarkers of Alzheimer's disease.

  2010cited by this paper
• Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study

  2010cited by this paper
• A robust method to estimate the intracranial volume across MRI field strengths (1.5T and 3T)

  2010cited by this paper
• Alzheimer's Disease Neuroimaging Initiative (ADNI)

  2010cited by this paper
• Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid β (1-42), Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop

  2010cited by this paper
• Revising the definition of Alzheimer's disease: a new lexicon.

  2010cited by this paper
• Low Incidence of Post-Lumbar Puncture Headache in 1,089 Consecutive Memory Clinic Patients

  2010cited by this paper
• Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity

  2010cited by this paper
• Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.

  2010cited by this paper
• Combining MR Imaging, Positron-Emission Tomography, and CSF Biomarkers in the Diagnosis and Prognosis of Alzheimer Disease

  2010cited by this paper
• Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

  2010influential reference
• To Know or Not to Know: Ethical Issues Related to Early Diagnosis of Alzheimer's Disease

  2010cited by this paper
• EFNS guidelines for the diagnosis and management of Alzheimer’s disease

  2010influential reference
• Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing.

  2010cited by this paper
• Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

  2010cited by this paper
• Relationship of dementia screening tests with biomarkers of Alzheimer's disease.

  2010cited by this paper
• Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

  2010cited by this paper
• Neurochemical dementia diagnostics: a simple algorithm for interpretation of the CSF biomarkers

  2009cited by this paper
• Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.

  2009cited by this paper
• Relationship of Cerebrospinal Fluid Markers to 11C-PiB and 18F-FDDNP Binding

  2009cited by this paper
• Magnetic Resonance Imaging Improves Cerebrospinal Fluid Biomarkers in the Early Detection of Alzheimer's Disease

  2009cited by this paper
• A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease

  2009cited by this paper
• Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment.

  2009cited by this paper
• Rapid Progression from Mild Cognitive Impairment to Alzheimer’s Disease in Subjects with Elevated Levels of Tau in Cerebrospinal Fluid and the APOE ε4/ε4 Genotype

  2009cited by this paper
• Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.

  2009cited by this paper
• MRI and CSF biomarkers in normal, MCI, and AD subjects

  2009cited by this paper
• Relationships between biomarkers in aging and dementia

  2009cited by this paper
• Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease

  2009cited by this paper
• Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

  2009cited by this paper
• CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

  2009cited by this paper
• Safety of lumbar puncture procedures in patients with Alzheimer's disease.

  2009cited by this paper
• Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

  2009cited by this paper
• Can CSF biomarkers or pre‐treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?

  2009cited by this paper
• Robust and conventional neuropsychological norms: diagnosis and prediction of age-related cognitive decline.

  2008cited by this paper
• JAMA patient page. Mild cognitive impairment.

  2008cited by this paper
• Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease.

  2008cited by this paper
• Do CSF total tau, phosphorylated tau, and β-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature

  2008cited by this paper
• JAMA patient page . Mild cognitive impairment.

  2008cited by this paper
• PET imaging of amyloid deposition in patients with mild cognitive impairment.

  2008cited by this paper
• THERMOREGULATION: RECENT CONCEPTS AND REMAINING QUESTIONS

  2008cited by this paper
• Reaction to a Dementia Diagnosis in Individuals with Alzheimer's Disease and Mild Cognitive Impairment

  2008cited by this paper
• Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins.

  2007cited by this paper
• Amnestic syndrome of the medial temporal type identifies prodromal AD

  2007cited by this paper
• Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.

  2007influential reference
• Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

  2007cited by this paper
• Intra-Individual Stability of CSF Biomarkers for Alzheimer's Disease over Two Years

  2007cited by this paper
• Cerebrospinal Fluid Biomarkers Predict Decline in Subjective Cognitive Function over 3 Years in Healthy Elderly

  2007cited by this paper
• Imaging and CSF Studies in the Preclinical Diagnosis of Alzheimer's Disease

  2007cited by this paper
• Longitudinal stability of CSF biomarkers in Alzheimer's disease.

  2007cited by this paper
• 18F-FDG PET Database of Longitudinally Confirmed Healthy Elderly Individuals Improves Detection of Mild Cognitive Impairment and Alzheimer's Disease

  2007cited by this paper
• Can primary care record review facilitate earlier diagnosis of dementia?

  2007cited by this paper
• CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study.

  2007cited by this paper
• CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment

  2007cited by this paper
• Diagnostic Accuracy of ELISA and xMAP Technology for Analysis of Amyloid β42 and Tau Proteins

  2007cited by this paper
• Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury

  2006cited by this paper
• Cerebrospinal fluid β-amyloid 1–42 concentration may predict cognitive decline in older women

  2006cited by this paper
• Faculty Opinions recommendation of Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

  2006cited by this paper
• Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans

  2006cited by this paper
• Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.

  2006cited by this paper
• CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.

  2006cited by this paper
• International quality control survey of neurochemical dementia diagnostics.

  2006cited by this paper
• Alzheimer's disease

  2006cited by this paper
• Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment.

  2006cited by this paper
• Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

  2005cited by this paper
• Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD

  2005cited by this paper
• Implications of the Facing Dementia Survey for health care professionals across Europe

  2005cited by this paper
• Cerebrospinal fluid protein biomarkers for Alzheimer’s disease

  2004cited by this paper
• Cerebrospinal fluid protein biomarkers for Alzheimer’s disease

  2004cited by this paper
• Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease

  2004influential reference

• An on-board journey from conventional to novel biomarkers for detection and monitoring of Alzheimer’s disease

  2026cites this paper
• Advances in plasma biomarkers for the diagnosis of Alzheimer's disease.

  2026cites this paper
• Associations of amyloid biomarkers with brain and cognitive changes from imaging, spinal fluid, and plasma

  2026cites this paper
• fNIRS-based early identification of mild cognitive impairment: a large-scale multi-paradigm study with ensemble machine learning models

  2026cites this paper
• Potential Role of Lymphovenous Bypass in Mitigating Alzheimer's Disease Dementia

  2025cites this paper
• Amplification-Free Dye-Labeled Digital Immunoassay: From Subpicomolar to Attomolar.

  2025cites this paper
• Generating MRI‐Derived CSF Proxy‐Markers to Predict and Visualize Alzheimer's Disease Progression

  2025cites this paper
• The many roads to dementia: a systems view of Alzheimer's disease

  2025cites this paper
• Associations between the logical memory test story recall metrics and plasma biomarkers for Alzheimer’s disease in individuals free of dementia

  2025cites this paper
• Artificial Intelligence for Personalized Prediction of Alzheimer's Disease Progression: A Survey of Methods, Data Challenges, and Future Directions

  2025cites this paper
• Cerebrospinal Fluid Biomarkers and Neuropsychological Abnormalities in Dementia: A Monocentric Study of Consecutive Patients

  2025cites this paper
• Exploring Experimental Approaches for Enhancing Alzheimer's Disease Prediction with MRI Data and Deep Learning

  2025cites this paper
• Statistical Learning for Personalized Prediction of Alzheimer's Disease Progression: A Survey of Methods, Data Challenges, and Future Directions

  2025cites this paper
• Usefulness of Cerebrospinal Fluid Alzheimer's disease biomarkers in older patients: Evidence from a national multicenter prospective study

  2025cites this paper
• Development and Validation of a Tool to Predict Onset of Mild Cognitive Impairment and Alzheimer Dementia

  2025cites this paper
• Uncovering cerebral blood flow patterns corresponding to Amyloid-beta accumulations in patients across the Alzheimer’s disease continuum using the arterial spin labeling

  2025cites this paper
• Plasma phosphorylated tau-217 correlates with brain atrophy, cognition, and cerebrospinal fluid biomarkers in a cognitively healthy community cohort

  2025cites this paper
• Biomarker changes associated with fornix deep brain stimulation in Alzheimer's disease

  2025cites this paper
• Shared and disease-specific pathways in frontotemporal dementia and Alzheimer’s and Parkinson’s diseases

  2025cites this paper
• Leveraging mHealth wearables for managing patients with Alzheimer's disease: a scoping review.

  2025cites this paper
• Exploring the Potential of Convolutional Neural Networks in Classifying Alzheimer’s Stages with Multi-biomarker Approach

  2025cites this paper
• Recent advances in nanomaterial-based biosensors for Alzheimer's disease diagnosis: a review.

  2025cites this paper
• SMAS: Structural MRI-based AD Score using Bayesian supervised VAE

  2025cites this paper
• A six-year risk assessment for dementia and Alzheimer's disease in the general population through immunoprecipitation-mass spectrometry plasma amyloid quantification

  2025cites this paper
• Matrix Optical Biosensor for Determining YKL-40/CHI3L1—A Biomarker Potentially Associated with Alzheimer’s Disease

  2025cites this paper
• Immunotherapy in Alzheimer’s Disease: Current Status and Future Directions

  2024cites this paper
• Machine learning of brain-specific biomarkers from EEG

  2024cites this paper
• The Associations of Phosphorylated Tau 181 and Tau 231 Levels in Plasma and Cerebrospinal Fluid with Cognitive Function in Alzheimer’s Disease: A Systematic Review and Meta-Analysis

  2024cites this paper
• Preoperative Biofluid Biomarkers for Predicting Postoperative Neurocognitive Disorders in Older Adults: A Systematic Review.

  2024cites this paper
• Graphene as basis of biological sensors for determining markers of neurodegenerative dementia

  2024cites this paper
• Discrepancies between self- and informant-ratings of functional abilities and objective cognition: predictors of bias in mild cognitive impairment

  2024cites this paper
• A Facile Strategy for Multiplex Protein Detection by a Fluorescent Microsphere-Based Digital Immunoassay.

  2024cites this paper
• Alzheimer's Disease Biomarker Analysis Using Targeted Mass Spectrometry

  2024influential citation
• Automatic offline-capable smartphone paper-based microfluidic device for efficient biomarker detection of Alzheimer's disease.

  2024cites this paper
• New horizons in the diagnosis and management of Alzheimer’s Disease in older adults

  2024cites this paper
• Relationship Between Cerebrospinal Fluid Alzheimer’s Disease Biomarker Values Measured via Lumipulse Assays and Conventional ELISA: Single-Center Experience and Systematic Review

  2024cites this paper
• On-chip microscale isoelectric focusing enhances protein detection limit.

  2024cites this paper
• Biomarkers for Alzheimer's Disease – An Overview

  2024cites this paper
• Biomimetically Inspired Micro‐Nano Hierarchical Structures of Rose Petals for Efficient SERS Sensing Applications

  2024cites this paper
• Nomination of a novel plasma protein biomarker panel capable of classifying Alzheimer’s disease dementia with high accuracy in an African American cohort

  2024cites this paper
• Plasma Aβ42/Aβ40 is sensitive to early cerebral amyloid accumulation and predicts risk of cognitive decline across the Alzheimer's disease spectrum

  2024cites this paper
• Cascaded Multimodal Deep Learning in the Differential Diagnosis, Progression Prediction, and Staging of Alzheimer’s and Frontotemporal Dementia

  2024cites this paper
• Breaking Barriers in Alzheimer’s Disease: the Role of Advanced Drug Delivery Systems

  2024cites this paper
• A nested cross validation approach to machine learning model performance evaluation on a small dataset for Creutzfeldt-Jakob disease diagnosis

  2024cites this paper
• 18F-Flortaucipir (AV1451) imaging identifies grey matter atrophy in retired athletes

  2024influential citation
• Recent advances in exploring new blood-based biomarkers for the early diagnosis of gastric cancer

  2024cites this paper
• The Effect of Resistance and Endurance Exercise on Alzheimer's Biomarkers: A Review Article

  2024cites this paper
• Hyperspectral retinal imaging in Alzheimer’s disease and age-related macular degeneration: a review

  2024cites this paper
• Cerebrospinal Fluid C1-Esterase Inhibitor and Tie-1 Levels Affect Cognitive Performance: Evidence from Proteome-Wide Mendelian Randomization

  2024cites this paper
• CSF biomarkers of neurotoxicity in childhood cancer survivors after cranial radiotherapy or surgery

  2024cites this paper
• Longitudinal Phospho-tau217 Predicts Amyloid Positron Emission Tomography in Asymptomatic Alzheimer's Disease

  2024cites this paper
• Potential application of aptamers combined with DNA nanoflowers in neurodegenerative diseases.

  2024cites this paper
• Detecting cognitive impairment through an age-friendly serious game: The development and usability of the spatial performance assessment for cognitive evaluation (SPACE)

  2024cites this paper
• Identification of Candidate Protein Biomarkers Associated with Domoic Acid Toxicosis in Cerebrospinal Fluid of California Sea Lions (Zalophus californianus)

  2024cites this paper
• Lower Prevalence of Asymptomatic Alzheimer's Disease Among Healthy African Americans

  2024cites this paper
• Optimized Pre-analytical Handling Protocol for Blood-Based Biomarkers of Alzheimer's Disease.

  2024cites this paper
• Colpocephaly and Partial Agenesis of Corpus Callosum with High Neurodegenerative Marker Levels

  2024cites this paper
• Alzheimer's disease biomarker utilization at first referral enhances differential diagnostic precision with simultaneous exclusion of Creutzfeldt‐Jakob disease

  2024cites this paper
• Cerebrospinal fluid p‐tau181, 217, and 231 in definite Creutzfeldt–Jakob disease with and without concomitant pathologies

  2024cites this paper
• Biofluid biomarkers for Alzheimer’s disease: past, present, and future

  2024cites this paper
• Analysis of the longitudinal stability of human plasma miRNAs and implications for disease biomarkers

  2024cites this paper
• Differential diagnosis of mild cognitive impairment of Alzheimer’s disease by Simoa p-tau181 measurements with matching plasma and CSF

  2024cites this paper
• Unraveling Alzheimer’s: the promise of aducanumab, lecanemab, and donanemab

  2024cites this paper
• The Biochemistry Behind Cognitive Decline: Biomarkers of Alzheimer’s Disease

  2023cites this paper
• Recommendations for reproducibility of cerebrospinal fluid extracellular vesicle studies

  2023cites this paper
• Alzheimer’s Disease Biomarker Detection Using Field Effect Transistor-Based Biosensor

  2023cites this paper
• Potential Roles and Future Perspectives of Chitinase 3-like 1 in Macrophage Polarization and the Development of Diseases

  2023cites this paper
• The effect of EEG and fNIRS in the digital assessment and digital therapy of Alzheimer’s disease: a systematic review

  2023cites this paper
• Understanding the Episodic Memory and Executive Functioning Axis Impairment in MCI Patients: A Multicenter Study in Comparison with CSF Biomarkers

  2023cites this paper
• Diagnostic Utility of Cerebrospinal Fluid Biomarkers in Patients with Rapidly Progressive Dementia

  2023influential citation
• Tutorial review for peptide assays: An ounce of pre-analytics is worth a pound of cure.

  2023cites this paper
• A how-to guide for a precision medicine approach to the diagnosis and treatment of Alzheimer's disease

  2023cites this paper
• The Sporadic Early‐onset Alzheimer's Disease Signature Of Atrophy: Preliminary Findings From The Longitudinal Early‐onset Alzheimer's Disease Study (LEADS) Cohort

  2023cites this paper
• Required improvements for cerebrospinal fluid-based biomarker tests of Alzheimer’s disease

  2023cites this paper
• Looking at the periphery—new hypothesis to look for new targets for Alzheimer’s disease therapy

  2023cites this paper
• Prediction of Proteins in Cerebrospinal Fluid and Application to Glioma Biomarker Identification

  2023cites this paper
• Emerging nanotechnology for Alzheimer's disease: From detection to treatment.

  2023cites this paper
• Forecasting individual progression trajectories in Alzheimer’s disease

  2023cites this paper
• Early Detection of Alzheimer’s Disease-Related Pathology Using a Multi-Disease Diagnostic Platform Employing Autoantibodies as Blood-Based Biomarkers

  2023cites this paper
• Altered granulocyte count and erythrocyte measures in middle-aged, healthy carriers of APOE and PICALM risk genes for Alzheimer's disease.

  2023cites this paper
• Mixture of regressions with multivariate responses for discovering subtypes in Alzheimer's biomarkers with detection limits.

  2023cites this paper
• Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer’s Disease

  2023cites this paper
• Meta-analysis of published cerebrospinal fluid proteomics data identifies and validates metabolic enzyme panel as Alzheimer’s disease biomarkers

  2023cites this paper
• Cell‐free RNA for the liquid biopsy of gastrointestinal cancer

  2023cites this paper
• CSF Aβ40 Levels Do Not Correlate with the Clinical Manifestations of Alzheimer’s Disease

  2023cites this paper
• Discerning the Prospects of miRNAs as a Multi-Target Therapeutic and Diagnostic for Alzheimer’s Disease

  2023cites this paper
• Plasma Aβ42/Aβ40 and phospho‐tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease

  2023cites this paper
• Self-assembly of Au nanocubes for ultrasensitive detection of Alzheimer's disease biomarkers by SERS.

  2023cites this paper
• Next-generation proteomics technologies in Alzheimer’s disease: from clinical research to routine diagnostics

  2023cites this paper
• Evaluation of Dimercaptosuccinic Acid-Coated Iron Nanoparticles Immunotargeted to Amyloid Beta as MRI Contrast Agents for the Diagnosis of Alzheimer’s Disease

  2023cites this paper
• Impact of pre‐analytical sample handling factors on plasma biomarkers of Alzheimer's disease

  2023cites this paper
• Selective Detection of Misfolded Tau From Postmortem Alzheimer’s Disease Brains

  2022cites this paper
• The Clinical Use of Alzheimer’s Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer’s Disease Consortium Survey

  2022cites this paper
• The Link between Obstructive Sleep Apnea and Neurocognitive Impairment: An Official American Thoracic Society Workshop Report

  2022cites this paper
• A novel approach to type 3 diabetes mechanism: The interplay between noncoding RNAs and insulin signaling pathway in Alzheimer's disease

  2022cites this paper
• Optimized sample preparation and data analysis for TMT proteomic analysis of cerebrospinal fluid applied to the identification of Alzheimer’s disease biomarkers

  2022cites this paper
• A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging

  2022cites this paper
• Different clinical outcomes between cerebral amyloid angiopathy-related inflammation and non-inflammatory form

  2022cites this paper
• Microglial Activation and Oxidative Stress in PM2.5-Induced Neurodegenerative Disorders

  2022cites this paper
• A novel Alzheimer's disease detection approach using GAN-based brain slice image enhancement

  2022cites this paper